Author:
Geertsen P F,Gore M E,Negrier S,Tourani J M,von der Maase H
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M (2002) Thirteen-year, long-term efficacy of interferon-2-alpha and interleukin-2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95: 1045–1050
2. Bordin V, Giani L, Meregalli S, Bukovec R, Vaghi MM, Mandala M, Paolorossi F, Ardizzoia A, Tancini G, Barni S, Frigerio F, Fumagalli L, Bordoni A, Valsuani G, Di Felice G, Lissoni P (2000) Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int 64: 3–8
3. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198–1220
4. Buter J, Sleijfer DT, van der Graaf WT, de Vries EG, Willemse PH, Mulder NH (1993) A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 20(6 Suppl 9): 16–21
5. Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D, Ferrozzi F, Giacosa R, Vaglio A (2001) Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 92: 2286–2296
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献